Leukocyte Surface Antigen CD47 Pipeline Review, H2 2019
Summary
According to the recently published report 'Leukocyte Surface Antigen CD47 Pipeline Review, H2 2019'; Leukocyte Surface Antigen CD47 Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47 pipeline Target constitutes close to 53 molecules. Out of which approximately 51 molecules are developed by companies and remaining by the universities/institutes.
Leukocyte Surface Antigen CD47 Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47 CD47 Cluster of Differentiation 47 or integrin associated protein IAP is a transmembrane protein encoded by the CD47 gene. It has a role in both cell adhesions by acting as an adhesion receptor for THBS1 on platelets, and in the modulation of integrins. It plays an important role in memory formation and synaptic plasticity in the hippocampus By similarity. It acts as a receptor for SIRPA. Interaction with SIRPG mediates cellcell adhesion, enhances superantigendependent Tcellmediated proliferation and costimulates Tcell activation. It plays an important role in membrane transport and/or integrin dependent signal transduction. It prevents premature elimination of red blood cells.
The report 'Leukocyte Surface Antigen CD47 Pipeline Review, H2 2019' outlays comprehensive information on the Leukocyte Surface Antigen CD47 Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Leukocyte Surface Antigen CD47 Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47 targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 10, 1, 28 and 9 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease and Metabolic Disorders which include indications Solid Tumor, Diffuse Large BCell Lymphoma, Lymphoma, NonHodgkin Lymphoma, Refractory Multiple Myeloma, Acute Lymphocytic Leukemia ALL, Acute Lymphoblastic Leukemia, Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia, Breast Cancer, Colorectal Cancer, Myelodysplastic Syndrome, NonSmall Cell Lung Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Glioblastoma Multiforme GBM, Ovarian Cancer, Pancreatic Cancer, Peritoneal Cancer, SmallCell Lung Cancer, BCell NonHodgkin Lymphoma, Blood Cancer, Cutaneous TCell Lymphoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Follicular Lymphoma, Hodgkin Lymphoma BCell Hodgkin Lymphoma, Leukemia, Marginal Zone Bcell Lymphoma, Melanoma, Refractory Chronic Lymphocytic Leukemia CLL, Relapsed Chronic Lymphocytic Leukemia CLL, TripleNegative Breast Cancer TNBC, Bladder Cancer, Cerebral Fatal Malaria, Chronic Lymphocytic Leukemia CLL, Colon Carcinoma, Diabetic Retinopathy, Gastric Cancer, Gastroesophageal GE Junction Carcinomas, Gastrointestinal Tract Cancer, Gliosarcoma, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, HighGrade Glioma, Leiomyosarcoma, Lung Cancer, Mantle Cell Lymphoma, Metastatic Brain Tumor, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Metastatic Transitional Urothelial Tract Cancer, Mycosis Fungoides, Myeloproliferative Disorders, Neuroendocrine Tumors, NonSmall Cell Lung Carcinoma, Oral Cavity Mouth Cancer, Oropharyngeal Cancer, Peripheral TCell Lymphomas PTCL, Sezary Syndrome, Thymic Carcinoma and Transitional Cell Cancer Urothelial Cell Cancer.
Scope
The report provides a snapshot of the global therapeutic landscape for Leukocyte Surface Antigen CD47 Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47
The report reviews Leukocyte Surface Antigen CD47 Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Leukocyte Surface Antigen CD47 Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47 targeted therapeutics and enlists all their major and minor projects
The report assesses Leukocyte Surface Antigen CD47 Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Leukocyte Surface Antigen CD47 Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47 targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Leukocyte Surface Antigen CD47 Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Leukocyte Surface Antigen CD47 Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope